(EMAILWIRE.COM, November 21, 2018 ) P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) pipeline Target constitutes close to 6 molecules. The latest report P Selectin-Pipeline Review, H2 2018, outlays comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)-P-selectin is a protein encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. In unactivated platelets P-selectin is stored in α-granules. P-selectin plays an essential role in the initial recruitment of leukocytes (white blood cells) to the site of injury during inflammation.
Download sample copy of this Report: http://www.reportsweb.com/inquiry&RW00012283726/sample
The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 2, 2, 1 and 1 respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Central Nervous System, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Mouth and Dental Disorders and Oncology which include indications Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Sickle Cell Disease, Inflammation, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Oral Mucositis, Periodontitis and Rhino sinusitis.
Furthermore, this report also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
-The report provides a snapshot of the global therapeutic landscape for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
-The report reviews P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
Get More Information about this Report: http://www.reportsweb.com/inquiry&RW00012283726/buying
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
